Stock Analysis

B3 - Brasil Bolsa Balcão Second Quarter 2024 Earnings: Beats Expectations

Published
BOVESPA:B3SA3

B3 - Brasil Bolsa Balcão (BVMF:B3SA3) Second Quarter 2024 Results

Key Financial Results

  • Revenue: R$2.46b (up 10% from 2Q 2023).
  • Net income: R$1.24b (up 18% from 2Q 2023).
  • Profit margin: 51% (up from 47% in 2Q 2023). The increase in margin was driven by higher revenue.
  • EPS: R$0.23 (up from R$0.18 in 2Q 2023).
BOVESPA:B3SA3 Earnings and Revenue Growth August 11th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

B3 - Brasil Bolsa Balcão Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 5.0%. Earnings per share (EPS) also surpassed analyst estimates by 8.8%.

Looking ahead, revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 2.6% growth forecast for the Capital Markets industry in South America.

Performance of the market in Brazil.

The company's shares are up 11% from a week ago.

Risk Analysis

Before you take the next step you should know about the 1 warning sign for B3 - Brasil Bolsa Balcão that we have uncovered.

Valuation is complex, but we're here to simplify it.

Discover if B3 - Brasil Bolsa Balcão might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.